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ABSTRACT
Background: The Democratic Republic of the Congo (DRC) is the third most affected country
worldwide by sickle cell disease (SCD). However, this disease is still orphaned in the country;
large-scale control actions are rare, and little is known about its management.
Objective: To assess current practices in the management of SCD in Kisangani, DRC.
Methods: This cross-sectional study was conducted in six health facilities in Kisangani.
It involved 198 presumed sickle cell patients attending the above health facilities. The study
focused on the sociodemographic and clinical data of the participants, obtained through a
clinical examination and their medical records. Diagnostic confirmation of SCD was made by
high-performance liquid chromatography coupled to mass spectrometry. Data were
analyzed using SPSS 20.0.
Results: The diagnosis of SCD was confirmed in 194 (98.0%; 95% CI: 94.9–99.2) participants,
while it was not confirmed in 4 (2.0%; 95% CI: 0.8–5.1) participants. The diagnosis was
mainly made by the Emmel test (42.9%). 45.8% of participants had previously been
transfused with the blood of their parents. Folic acid was taken by 48.5% of participants and
the previous intake of hydroxyurea was reported in 5.1% of participants. The participants
vaccinated against Pneumococcus were 13.6% and against Haemophilus influenzae type b
28.3%. Penicillin prophylaxis was received by only 1.5% and malaria prophylaxis by 11.6% of
participants.
Conclusion: Standard-care practices for SCD patients in Kisangani are insufficient. The
Congolese government should regard this disease as a health priority and consider actions








Democratic Republic of the
Congo
Introduction
Sickle cell disease (SCD), the most common inherited
genetic disease worldwide, is currently a major
global health concern, especially in sub-Saharan
Africa (SSA). Indeed, it is estimated that more than
300,000 babies with SCD are born annually in this
region, representing approximately 75-85% of all
births of children with SCD worldwide [1–4]. Moreover,
according to theWorld Health Organization (WHO), 50-
80% of SCD children who are born in SSA die before
their 5th birthday, usually from an infection or severe
anemia [3–5]. Without a good management, the
disease causes complications in multiple body
organs. Some of the most common associated morbid-
ities include chronic pain and intermittent painful epi-
sodes, anemia, musculoskeletal problems, stroke,
acute chest syndrome and recurrent infections. These
complications often co-exist, affecting the quality of
life for patients, and if not adequately managed, may
lead to death.
Keith Wailoo’s study [6] which provided a back-
ground on the evolution of the life expectancy in
persons with SCD from 1910 to 2000, showed that
specific interventions in the United States of America
since the 1970s have increased the life expectancy of
SCD patients from less than 15 years before 1970s to
over 40 years in 2000. The importance of specific inter-
ventions was also highlighted in the study by Rahimy
et al. [7] in Benin, who observed that early neonatal
screening for SCD followed by enrollment in a
follow-up program, had significantly reduced the
under-five mortality rate to a rate 10 times lower
than the overall under-five mortality rate in the Repub-
lic of Benin, i.e. 15.5 per 10,000.
It is acknowledged that a comprehensive manage-
ment of SCD including specific interventions such as
neonatal screening, early diagnosis and preventive
penicillin therapy, Pneumococcal and Haemophilus
influenzae vaccination, malaria prophylaxis in malaria-
endemic areas, improved blood safety, hydroxyurea
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administration, vitamin supplements such as folic acid,
early diagnosis of complications and their prompt
management may decrease sickle cell disease-related
morbidity and mortality, preventing organic damage
and therefore improve the quality of life and the life
expectancy of SCD patients [3,4,8,9].
In theWHOAfricanRegion, itwas recommended that
by 2020, 50% of states with high prevalence of SCD,
including the Democratic Republic of the Congo (DRC),
should have developed and implemented well-
designed national programs to combat SCD as part of
their national strategic health plans. In addition, a com-
prehensive care policy was recommended including
the use of antibiotic prophylaxis and antimalarial
drugs, vaccinations, permanent medical follow-up and
early detection and management of complications [5].
But this remains amajor challenge inmanycountries [8].
The DRC is the third most affected country in the
world by SCD [1]. However, despite its epidemiological
importance, the disease is still orphaned and large-
scale control actions are scarce. This setting suggests
that there may be a poor utilization of standard-of-
care practices for SCD patients in the country. Since
little is known about this in the DRC, especially in the
eastern part of the country, the purpose of this study
was to assess current practices regarding the diagnosis
of SCD and the features of its management in Kisan-
gani (North-eastern DRC).
Material and methods
Study design and setting
This health facility-based survey was a cross-sectional
study carrying out in Kisangani among presumed
SCD patients between August 2018 to July 2019,
using a paper-based and semi-structured question-
naire developed and pre-tested by a team study
from the Faculty of Medicine and Pharmacy of the Uni-
versity of Kisangani.
Kisangani is the capital city of Tshopoprovince and the
third largest urbanized city in the DRC, comprising 1.6
million inhabitants [10], with a neonatal prevalence of
SCDof about 1%and 23.3% for the homozygous andhet-
erozygous forms, respectively [11]. A total of six facilities in
Kisangani were selected for this study including three
public (University hospital of Kisangani, Reference
General Hospital of Makiso and Kabondo) and three
private (Health Centers of Alabul, Maison médicale and
Graciafondation)healthfacilities.Thechoiceofthesefacili-
tieswas justifiedbytheirhighattendancebySCDpatients.
Study population and recruitment
All participants were presumed SCD patients enrolled
from patients visiting the selected health facilities for
any kind of medical care. The inclusion criteria were
being registered and followed up as SCD patient in the
above health facilities, being present at the time of the
survey, and having given free and informed consent to
participate in the study. For children under 16 years of
age, the consent of parents or guardians was required.
The requested minimum number(n) of participants to
include was obtained by setting 95% confidence level,
80% statistical power, and considering estimated the
prevalence of the sickle cell trait of 23.3% in Kisangani
[11], DRC. Thus, at least 117 participants were required
to be included in the study.
Data collection
After filling the sociodemographic data (age and sex),
the participants underwent a clinical examination
which allowed us to collect data on diagnostic
methods of the SCD, immunization status (against
Pneumococcus, Haemophilus influenza type b [Hib], Sal-
monella sp), chemoprophylaxis (Penicillin and antima-
larial prophylaxis) and specific treatment of SCD (folic
acid and hydroxyurea intake, and blood transfusion
[history, indication and type of blood transfusion,
and origin of transfused blood]). For children under
16 years of age, information were obtained from
their parents or guardians. In complement to the clini-
cal examination, we used the medical records of the
patients. At the end of the session, capillary whole
blood was collected by finger sampling using dried
blood spots for laboratory diagnosis to confirm SCD.
The samples were sent to the Biochemical Genetics
Laboratory of CHU (Centre Hospitalier Universitaire)
of Liège (Belgium) where the screening of SCD was
carried out by high-performance liquid chromato-
graphy coupled to mass spectrometry (TQ5500 –
Sciex – Framingham, MA 01701 U.S.A) [12,13]. The lab-
oratory results were collected on standardized sheets.
Ethical statement and statistical analysis
Ethical clearance was obtained from the Ethics Com-
mittee of the University of Kisangani (Réf. UNIKIS/
CER/007/2018). Furthermore, Freely-given and
informed consent to participate in the study was
obtained from all participants. For children under 16
years of age, the consent of parents or guardians was
required. Data were entered into an Excel file and ana-
lyzed on SPSS 20.0 (Chicago, IL). Proportions were cal-
culated for categorical variables; and the results were
presented as a 95% confidence interval (CI) using the
Wilson score bounds. For the quantitative variables,
mean and standard deviation were calculated.
Results
A total of 221 participants were evaluated for eligibility
for the study. Among them, 198 participants were
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finally included in the study whereas 23 were excluded
because they did not consent (n = 17) and were absent
in Kisangani at the time of the survey (n = 6) (Figure 1).
Data on the sociodemographic characteristics of par-
ticipants are shown in Table 1. In brief, the majority
of participants were female and under 16 years of
age (mean: 13.74; SD: 9.34; Min: 2; Max: 74).
As shown in Figure 1, 194 (98.0%; 95% CI: 94.9–99.2)
presumed SCD patients were confirmed as SCD
patients with the high-performance liquid chromato-
graphy coupled to mass spectrometry (TQ5500 –
Sciex – Framingham, MA 01701 U.S.A) whereas 4
(2.0%; 95% CI: 0.8–5.1) presumed SCD patients were
not confirmed. When investigating the diagnostic
method used in the past for these participants to be
considered SCD patients, in general, the Emmel test
was predominantly used with 85 (42.9%) participants,
while hemoglobin electrophoresis was used in only
12.1% of participants. In 12 (6.1%) participants, the
diagnosis was made only on the basis of the clinic
and family history of SCD. Of the four participants in
whom the diagnosis of SCD was not confirmed, two
(50%) were males under 16 years of age, and all were
previously diagnosed on the basis of the Emmel test
(Table 1).
The study showed that 79.3% of participants had
history of blood transfusion and 45.8% had previously
been transfused with blood units from their parents. In
all cases, it was episodic transfusions (Table 1).
Although irregularly, folic acid was taken by 48.5% of
participants and previous intake of hydroxyurea was
reported in only 5.1% of participants. In addition,
only 13.6% of participants were vaccinated against
Pneumococcus and 28.3% against Hib. Penicillin pro-
phylaxis was received by only 1.5% of participants
and malaria chemoprophylaxis by 11.6% (Table 2).
Discussion
We herein report on current practices regarding the
diagnosis of SCD and the features of its management
in Kisangani, DRC. Overall, our findings showed that
98% of the participants were truly SCD patients
whereas 2% were not because of the poor perform-
ance of the diagnostic tests used. In addition, the
vast majority of patients did not receive appropriate
healthcare. These findings show that SCD patients in
Kisangani are poorly managed by the existing health-
care system.
In high-income countries, screening of SCD is done
by high-performance liquid chromatography, capillary
electrophoresis and sometimes isoelectric focusing
which are well-established methods for haemoglobi-
nopathies screening. But, as shown in this study, diag-
nosis of SCD in the DRC is still largely based on the
Emmel test and even only on the basis of clinical exam-
ination. Currently, capillary electrophoresis and/or iso-
electric focusing is performed in only a very limited
number of health facilities in DRC, mainly in Kinshasa
and Lubumbashi, which are the two largest cities in
the country. Elsewhere, these methods are quasi
non-existent. In the context of lack of advanced equip-
ment, local and realistic solutions are to be considered
in order to improve the diagnosis of SCD in the DRC.
Figure 1. Participant recruitment.
HEMATOLOGY 201
The large-scale use of point-of-care tests such as
«HemoType SC®» and «Sickle Scan®» recently intro-
duced in SSA and in the DRC through pilot projects
[14], are interesting options. Indeed, these tests
based on lateral flow immunoassay devices (Hemotype
SC®) or chromatographic immunoassay approach
(Sickle Scan®) have demonstrated excellent analytical
performance in the screening of sickle cell disease
[14,15] and would make it possible to bypass the diag-
nostic pitfalls associated to the Emmel test.
Our findings showed that folic acid was taken by
less than half of the participants, contrasting with the
results of Aloni et al. in Kinshasa [16] who observed
that 98.0% of the SCD patients were taking folic acid.
The fact that Aloni et al conducted their study in a
center dedicated to the management of the SCD can
account for this result. It has been hypothesized that
patients with SCD are at an increased risk for folate
deficiency [17,18]. For this reason, SCD patients com-
monly take folic acid on the premise that it will
replace depleted folate stores and reduce the symp-
toms of anemia. However, this has not yet been for-
mally demonstrated and is still controversial [19]. In
our opinion, folic acid supplementation is required in
the DRC. Indeed, the precarious nutritional conditions
of SCD patients due, among other things, to poverty
and the financial burden of the disease on families
owing to lack of health insurance system in the
country, expose them to various nutritional
deficiencies.
Hydroxyurea is the only substantive treatment for
SCD. Tshilolo et al. [2], Ofakunrin et al. [20] and Thorn-
burg et al. [21] have recently demonstrated in SSA the
safety and benefit of using hydroxyurea in SCD
patients indicating the need for wider access to this
drug. In this study, only 5.1% of SCD patients have
ever been treated with hydroxyurea. Whether this is
due to the limited financial accessibility to this mol-
ecule, its rarity in our area, the lack of clinical indi-
cations, concerns about side effects, the lack or
insufficient knowledge of the caregivers about this
drug remains to be determined. Studies assessing
the barriers to the use of hydroxyurea in SCD patients
in the DRC, and more generally in SSA are therefore
needed as well as actions related to this drug supply
in terms of quantity, quality, availability, and affordabil-
ity to be considered by the public health authorities.
Local production of generic hydroxyurea tablets
would be an interesting option as it could make this
drug more available and financially affordable for
patient. Our result is in accordance with that of Aloni
et al in Kinshasa who observed that only 2% of SCD
patients were taking hydroxyurea [16], and that of Ofa-
kunrin et al in Nigeria [20] who reported a low use of
hydroxyurea among Nigerian SCD patients.
As shown in this study, 45.8% of SCD patients had
previously been transfused with blood units from
their parents, exposing them to complications.
Indeed, it is recognized that increasing hematocrit
without decreasing the percentage of circulating
sickle cell constitutes a risk factor of stroke and other
complications in SCD patients [22]. This may occur
when blood units with hemoglobin AS, such as that









Mean, SD 13.74 9.34
Min, Max 2 74
Diagnosis made on the basis of
Clinical manifestations and history of SCD in the
family
12 6.1
Emmel test 85 42.9
Hb electrophoresis 24 12.1
Don’t know 77 38.9
History of blood transfusion
Yes 157 79.3
No 34 17.2
Don’t know 7 3.5
Indication of blood transfusion (n = 157)
Anemia 118 75.2
Pain crisis 12 7.6
Don’t know 27 17.2




Don’t know 26 16.6
Type of transfusion
Episodic transfusion 157 100
Chronic transfusion (simple/red cell exchange) 0 0
Note: SD, Standard deviation; MIN, Minimum; MAX, Maximum; Hb,
Hemoglobin.
Table 2. Distribution of 198 participants according to whether
they received specific therapy, immunization, and anti-
infectious chemoprophylaxis.
Variable
Yes No Don’t know
n (%) n (%) n (%)
Specific therapy
Folic acid intakea 96 (48.5) 69 (34.8) 33 (16.7)
Hydroxyurea intake 10 (5.1) 188 (94.9) 0 (0)
Immunization
Against Pneumococcus (PCV-13)b 27 (13.6) 160 (80.8) 11 (5.6)
Against Haemophilus influenzaeb 56 (28.3) 131 (66.2) 11 (5.5)
Against Salmonella sp 0 (0) 188 (94.9) 10 (5.1)
Chemoprophylaxis
Penicillin prophylaxis 3 (1.5) 195 (98.5) 0 (0)
Antimalarial prophylaxisa 23 (11.6) 153 (77.3) 22 (11.1)
Note: PCV, Pneumococcal Conjugate Vaccine.
aIrregular intake.
bReceived during EPI campaigns (EPI, Expanded Program on
Immunization).
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of the parents of SCD patients, are administered to
patients with SCD. In the context of the DRC where
the need for blood is always greater than the supply,
and where patients often arrive at the emergency ser-
vices with severe anemia, the question of whether AS
donors should be excluded from donating in SCD
patients is crucial but difficult to answer. Moreover,
Batina-Agasa and colleagues [23] recently demon-
strated that the prevalence of hemoglobin AS among
blood donors in the DRC was 23.2%.
None of the patients were in a chronic transfusion
program. A number of factors can account for this
result. The lack of transcranial Doppler equipment to
identify children with SCD at risk of stroke, the lack
of erythrocytapheresis equipment and the absence of
quantitative Hemoglobin S(HbS) and Hemoglobin F
(HbF) assays in our area do not make it possible to con-
sider a chronic transfusion program. In addition, the
persistence of family and remunerated blood donors
is a potential barrier to chronic transfusion in our
setting, since a high risk of transfusion-transmitted
infections has been reported in this category of
donors [24,25]. Moreover, the guidelines recommend
to irradiate donations from first or second-degree rela-
tives, even if the patient is immunocompetent, to
prevent transfusion-associated graft-vs-host disease
(TA-GVHD) [26]. However, data regarding TA-GVHD
are not available in DRC.
Encapsulated bacteria especially Streptococcus
pneumoniae and Hib are an important cause of mor-
bidity and death in SCD patients mainly in children.
Therefore, penicillin prophylaxis and immunization
against these two bacteria are measures widely
accepted in the management of SCD and their effec-
tiveness has been well demonstrated [9]. In this
study, we noticed that only 13.6% of participants
were vaccinated against Pneumococcus and 28.3%
against Hib. In addition, all participants were vacci-
nated in childhood according to the immunization
schedule in DRC, throughout the Expanded Program
on Immunization (EPI) campaigns. These results can
mostly be attributed to the fact that it was in 2009
and 2011 respectively that the Hib and Pneumococcal
conjugate vaccines (PCV-13) were introduced in the EPI
in DRC. Consequently, SCD patients born before 2009
did not benefit from these vaccines. The CDC
(Centers for Disease Control and Prevention) rec-
ommends vaccination of SCD patients over 5 years of
age who have not been immunized or who have
been incompletely immunized [27]. Since vaccines
against Pneumococcus and Hib are available in the
DRC, a government policy that can allow immunization
of unvaccinated SCD patients in childhood is required.
Very few SCD patients (1.5%) were receiving penicil-
lin prophylaxis. Elsewhere, Galadanci et al. [28] in
Nigeria found that few clinics provided penicillin pro-
phylaxis or pneumococcal vaccination for patients
with SCD. Although bacterial resistance to penicillin
is increasingly being observed, penicillin prophylaxis
is still widely recommended for children with SCD
and there is evidence that it significantly reduces the
risk of pneumococcal and Hib infection in children
with homozygous SCD [5,29,30].
The DRC is the second most malaria-affected
country worldwide [31]. As noted in this study,
malaria chemoprophylaxis was undertaken by only
11.6% of the participants and this was done irregularly,
whereas the WHO recommends this prophylaxis in
SCD patients living in malaria-endemic areas [5]. The
lack of policy regarding antimalarial chemoprophylaxis
for SCD patients in DRC may explain this result. Indeed,
in this country, malaria chemoprophylaxis is currently
recommended only for pregnant women. A systematic
review and network meta-analysis of the safety and
efficacy of antimalarial therapy in SCD by Frimpong
and colleagues showed that antimalarial prophylaxis
reduces the incidence of clinical malaria in children
with the disease [32]. Studies on the co-morbidity of
SCD and malaria are therefore necessary in the DRC.
As a first step, the impact of malaria on the SCD and
vice versa should be determined. Then, in a second
step, the following questions should be assessed:
which drug for which treatment regimen for malaria
chemoprophylaxis in SCD patients and for what
result? Elsewhere, these questions still arise [32].
In conclusion, this study showed that there is insuffi-
cient use of standard-care practices for SCD patients in
Kisangani. The Congolese government should regard
this disease as a health priority and consider actions
to improve its management. The implementation of
dedicated and well-equipped SCD health centers and
the training of health-care providers will improve the
treatment of sickle cell patients.
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